Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.
Human papillomavirus (HPV) vaccines based on L1 virus-like particle (VLP) can prevent genital HPV infection and associated lesions after three intramuscular injections. Needle-free administration might facilitate vaccine implementation, especially in developing countries. Here we have investigated rectal and vaginal administration of HPV16 L1 VLPs in mice and their ability to induce anti-VLP and HPV16-neutralizing antibodies in serum and in genital, rectal and oral secretions. Rectal and vaginal immunizations were not effective in the absence of adjuvant. Cholera toxin was able to enhance systemic and mucosal anti-VLPs responses after rectal immunization, but not after vaginal immunization. Rectal immunization with Resiquimod and to a lesser extent Imiquimod, but not monophosphoryl lipid A, induced anti-HPV16 VLP antibodies in serum and secretions. Vaginal immunization was immunogenic only if administered in mice treated with nonoxynol-9, a disrupter of the cervico-vaginal epithelium. Our findings show that rectal and vaginal administration of VLPs can induce significant HPV16-neutralizing antibody levels in secretions, despite the fact that low titers are induced in serum. Imidazoquinolines, largely used to treat genital and anal warts, and nonoxonol-9, used as genital microbicide/spermicide were identified as adjuvants that could be safely used by the rectal or vaginal route, respectively.
Institute of Microbiology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Bugnon 48, CH-1011 Lausanne, Switzerland.
Dominique
D
Fraillery
Nathalie
N
Zosso
Denise
D
Nardelli-Haefliger
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000282:Administration, Intravaginal; D000285:Administration, Rectal; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood / Q000502:physiology; D000917:Antibody Formation / Q000187:drug effects; D036022:Capsid Proteins / Q000008:administration & dosage* / Q000276:immunology; D002772:Cholera Toxin / Q000008:administration & dosage; D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D008050:Lipid A / Q000008:administration & dosage / Q000031:analogs & derivatives; D051379:Mice; D009055:Mouth / Q000378:metabolism; D017137:Nonoxynol / Q000008:administration & dosage; D009856:Oncogene Proteins, Viral / Q000008:administration & dosage* / Q000276:immunology; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D012007:Rectum / Q000378:metabolism; D014614:Vaccines, Synthetic / Q000008:administration & dosage; D014621:Vagina / Q000378:metabolism
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D036022:Capsid Proteins; D007093:Imidazoles; D008050:Lipid A; D009856:Oncogene Proteins, Viral; D053918:Papillomavirus Vaccines; D014614:Vaccines, Synthetic; D017137:Nonoxynol; C063317:L1 protein, Human papillomavirus type 16; D002772:Cholera Toxin; C048436:monophosphoryl lipid A; C402365:resiquimod